NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 54.75

+1.4%

10:51 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (170)	10/28/2006 2:25:54 PM
From: Ian@SI	of 507

Tuck, Many thanks. Your research hit the spot. ;-) From pp 3-4 of the PDF: Nektar Molecule Engineering was essential to the creation of several approved and marketed products, including PEGASYS® (peginterferon alfa-2a) for hepatitis C, marketed by Roche; Neulasta™ (pegfilgrastim) for neutropenia associated with cancer chemotherapy, marketed by Amgen; PEG-Intron® (peginterferon alfa-2b) for hepatitis C, marketed by Schering-Plough; and SprayGel® for post-surgical adhesion prevention, marketed by Confluent Surgical. Further, through a partnership with Enzon, Nektar has the exclusive rights to sub-license Enzon’s PEG technologies to third parties – providing Nektar with the largest set of proprietary PEG technologies available for pharmaceutical applications. The NKTR brochure came a year after the ENZN PR re the settlement. Nevertheless, a call to IR or a 10K reading may be necessary to better understand any specific PEGed drug. It does seem that there may be substantial revenue potential besides Exubera. Again thanks for your effort. Have a good weekend, Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next